Cynata Therapeutics ROA 2024

Cynata Therapeutics Aktienanalyse

What does Cynata Therapeutics do?

Cynata Therapeutics Ltd is a biotechnology company focused on the development of novel stem cell therapies. The company was founded in 2011 and is headquartered in Melbourne, Australia. The founders of Cynata Therapeutics were searching for a more effective type of stem cell therapy that would surpass the limitations of existing technologies. They developed a method to generate an unlimited number of stem cells from foreign sources, making them largely immunologically neutral. These stem cells are called Cymerus stem cells and are at the core of Cynata Therapeutics' business model. In January 2015, the company went public and raised $8 million to further advance its research and development. Today, Cynata Therapeutics has branches in Australia and the USA and employs over 20 people. The business model of Cynata Therapeutics is based on manufacturing and marketing stem cell therapies using the Cymerus technology. The company's stem cell products aim to treat a wide range of diseases and injuries, including heart disease, kidney disease, neurological disorders, and various types of cancer. One of the key sectors of Cynata Therapeutics is clinical research. The company is currently conducting several clinical trials to investigate the efficacy of its stem cell therapies. For example, a recently completed study examined the use of Cymerus stem cells to treat graft-versus-host disease (GVHD), a potentially life-threatening complication that can occur after a bone marrow transplant. Cynata Therapeutics also collaborates closely with other companies and organizations in the biotechnology industry to further develop and market its technologies and therapies. In 2017, the company signed a strategic partnership with Fujifilm Cells Co. Ltd., a subsidiary of Fujifilm. One of Cynata Therapeutics' most well-known products is currently a stem cell therapy called CYP-001. This product aims to treat the physical and functional impairments that can occur after a heart attack. The therapy consists of Cymerus stem cells injected into the damaged heart tissue to repair diseased cells and rebuild the heart. Cynata Therapeutics is also committed to expanding its technologies and therapies worldwide. The company is currently working to market its products and services in Europe and Asia and has already formed distribution partnerships in several countries. Although Cynata Therapeutics is still in the early stages of its business development, it has the potential to become a leading player in the field of stem cell therapy. Through its innovative technologies and extensive clinical research activities, the company has managed to attract a growing number of customers and investors who believe that its products and services could have significant impacts on the healthcare industry. Cynata Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Cynata Therapeutics's Return on Assets (ROA)

Cynata Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Cynata Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Cynata Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Cynata Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Cynata Therapeutics stock

What is the Return on Assets (ROA) of Cynata Therapeutics this year?

The Return on Assets (ROA) of Cynata Therapeutics is -1.16 undefined this year.

What was the ROA of Cynata Therapeutics compared to the previous year?

The ROA of Cynata Therapeutics has increased by 466.39% compared to the previous year.

What consequences do high ROA have for investors of Cynata Therapeutics?

A high ROA is advantageous for investors of Cynata Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Cynata Therapeutics?

A low ROA can be unfavorable for investors of Cynata Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Cynata Therapeutics affect the company?

An increase in ROA of Cynata Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Cynata Therapeutics impact the company?

A reduction in the ROA of Cynata Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Cynata Therapeutics?

Some factors that can influence the ROA of Cynata Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Cynata Therapeutics important for investors?

The ROA of Cynata Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Cynata Therapeutics take to improve ROA?

To improve ROA, Cynata Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Cynata Therapeutics pay?

Over the past 12 months, Cynata Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cynata Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Cynata Therapeutics?

The current dividend yield of Cynata Therapeutics is .

When does Cynata Therapeutics pay dividends?

Cynata Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cynata Therapeutics?

Cynata Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cynata Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cynata Therapeutics located?

Cynata Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cynata Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cynata Therapeutics from 11/1/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Cynata Therapeutics pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Cynata Therapeutics in the year 2023?

In the year 2023, Cynata Therapeutics distributed 0 AUD as dividends.

In which currency does Cynata Therapeutics pay out the dividend?

The dividends of Cynata Therapeutics are distributed in AUD.